Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $16.36 USD
Change Today -0.04 / -0.24%
Volume 664.9K
As of 8:10 PM 07/28/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

201 Elliott Avenue West

Seattle, WA 98119

United States

Phone: 206-676-5000

Fax: 206-676-5005

OMS824 in healthy subjects. The company is also conducting a clinical trial to evaluate target occupancy of OMS824 using positron emission tomography, scans in healthy subjects by measuring the extent to which OMS824 binds to PDE10 in the striatum, a region of the brain that has been linked to a wide range of diseases that affect cognition. The company is evaluating OMS824 in two Phase 2 programs: one in patients with stable schizophrenia and the other in Huntington's disease patients. Mannan-binding lectin-associated serine protease (MASP) Program - OMS721 MASP-2, is a novel pro-inflammatory protein target involved in activation of the complement system, which is an important component of the immune system. The company is developing MASP-2 antibodies. The company completed a series of in vivo studies using either proprietary MASP-2 knock-out mice and/or MASP-2 antibodies in established models of disease that are linked to activation of the complement system. In 2013, the company obtained regulatory clearance to start a Phase 1 trial in Europe evaluating OMS721, which is scheduled to be concluded in April 2014. The company has initiated a Phase 2 program for OMS721. The company holds worldwide exclusive licenses to rights related to MASP-2, the antibodies targeting MASP-2 and the therapeutic applications for those antibodies from the University of Leicester, from its collaborator, Medical Research Council at Oxford University (MRC), and from Helion Biotech ApS (Helion). Under its exclusive license agreements with the University of Leicester and MRC, the company has agreed to pay royalties to each of the University of Leicester and MRC that are a percentage of any proceeds the company receive from the licensed technology during the terms of the agreements. The company retains worldwide exclusive licenses from these institutions to develop and commercialize any intellectual property rights developed in the sponsored research. In 2010, the company entered into an exclusive license agreement with Helion, pursuant to which it received a royalty-bearing, worldwide exclusive license to all of Helion's intellectual property rights related to MASP-2 antibodies, polypeptides and methods in the field of inhibition of mannan-binding lectin-mediated activation of the complement system for the prevention, treatment or diagnosis of any disease or condition. Alternative and/or Lectin Pathway: As part of its MASP program, the company has also identified the key activators of the alternative pathway. In its peroxisome proliferator-activated receptor gamma, program, the company is developing proprietary compositions that include peroxisome proliferator-activated receptor gamma agonists for the treatment and prevention of addiction to substances of abuse, which may include opioids, nicotine and alcohol. The company acquired the patent applications and related intellectual property rights for its peroxisome proliferator-activated receptor gamma program in 2009 from Roberto Ciccocioppo, Ph.D. of the Università di Camerino, Italy, pursuant to a patent assignment agreement. OMS201-Urology OMS201 is the company's PharmacoSurgery product being developed for use during urological procedures, including ureterscopy for removal of ureteral or renal stones. OMS201 is a proprietary combination of an anti-inflammatory API and a smooth muscle relaxant API, and is intended for local delivery to the bladder, ureter, urethra, and other urinary tract structures by inclusion in the standardly used irrigation solution used during endoscopic urological procedures. Preclinical Programs PDE7 Program - OMS527 The company's phosphodiesterase 7, or PDE7, program is based on its discoveries of previously unknown links between PDE7 and any addiction or compulsive disorder and between PDE7 and any movement disorders, such as Parkinson's disease. PDE7 appears to modulate the dopaminergic system, which plays a significant role in regulating both addiction and movement. Under an agreement with Daiichi Sankyo Co., Ltd. or Daiichi Sankyo, the company holds an exclusive license to PDE7 inhibitors claimed in certain patents and pending pa


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OMER:US $16.36 USD -0.04

OMER Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OMER.
View Industry Companies

Industry Analysis


Industry Average

Valuation OMER Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 723.5x
Price/Book 28.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 625.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OMEROS CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at